Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at BofA Securities
May 10, 2024 5:24 AM EDTBofA Securities analyst Tazeen Ahmad lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $26.00) while maintaining a Neutral rating.
The analyst comments "ACAD reported 1Q24 Daybue revenues of $75.9mn slightly missing their 1Q guidance of $76-82mn. Mgmt attributed the 1Q... More
